Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats

European Neuropsychopharmacology

Volumn 17, Issue 9, 2007, Pages 616-626

  Shirayama, Yukihiko ^a   Yamamoto, Ayaka ^a   Nishimura, Tomoko ^a   Katayama, Seiji ^a   Kawahara, Ryuzou ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Choline; Choline acetyltransferase; Cocaine; Cognition; Dynorphin; Phencyclidine

Indexed keywords

2 (2 OXO 1 PYRROLIDINYL) N (5,6,7,8 TETRAHYDRO 2,3 DIMETHYLFURO[2,3 B]QUINOLIN 4 YL)ACETAMIDE; CARBACHOL; CHOLINE ACETYLTRANSFERASE; COCAINE; DYNORPHIN A; PHENCYCLIDINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; LOCOMOTION; MALE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; SEPTUM PELLUCIDUM; TASK PERFORMANCE;

ACETYLCHOLINE; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CHOLINE O-ACETYLTRANSFERASE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; MALE; MENTAL DISORDERS; MOTOR ACTIVITY; NEURONS; PHENCYCLIDINE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SEPTUM OF BRAIN; TIME FACTORS;

EID: 34447531744     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.02.011     Document Type: Article

References (80)

1. Adams B., and Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 18 (1998) 5545-5554
2. Akaike A., Maeda T., Kaneko S., and Tamura Y. Protective effect of MKC-231, a novel high affinity choline uptake enhancer, on the glutamate cytotoxicity in cultured cortical neurons. Jpn. J. Pharmacol. 76 (1998) 219-222
3. Bella A., Sershen H., Serra M., Koneru R., and Javitt D.C. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology 28 (2003) 34-44
4. Bessho T., Takashina K., Ohshima C., and Egawa M. Increase in acetylcholine release by MKC-231, a novel choline uptake enhancer, in the hippocampus of AF64A-treated rats. Jpn. J. Pharmacol. 64 (1994) 230P (Suppl)
5. Bessho T., Takashina K., Tabata R., Ohshima C., Chaki H., Yamabe H., and Egawa M. Effect of the noble high affinity choline uptake enhancer 2-(2-oxo-pyrrolidin-1-yl)-N-(2,3-dimetyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide on deficits of water maze learning in rats. Arzneim.-Forsch./Drug Res. 46 (1996) 369-373
6. Broadbent N.J., Squire L.R., and Clark R.E. Spatial memory, recognition memory, and the hippocampus. Proc. Natl. Acad. Sci. U S A 101 (2004) 14515-14520
7. Bunce J.G., Sabolek H.R., and Chrobak J.J. Timing of administration mediates the memory effects of intraseptal carbachol infusion. Neuroscience 127 (2004) 593-600
8. Carlsson A., Waters N., Waters S., and Carlsson M.L. Network interactions in schizophrenia - therapeutic implications. Brains Res. Rev. 31 (2000) 342-349
9. Chartoff E.H., Heusner C.L., and Palmiter R.D. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 30 (2005) 1324-1333
10. Crawford C.A., McDougall S.A., Bolanos C.A., Hall S., and Berger S.P. The effects of the kappa agnoist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacology 120 (1995) 392-399
11. 3H]AF-DX384 is reduced in the caudate-putamen of subjects of schizophrenia. Life Sci. 64 (1999) 1761-1771
12. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol. Psychiatry 48 (2000) 381-388
13. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10 and 46 and the effects of neuroleptic drug treatment. Am. J. Psychiatry 158 (2001) 918-925
14. Dalley J.W., Cardinal R.N., and Robbins T.W. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci. Biobehav. Rev. 28 (2004) 771-784
15. Daniel J.M., and Dohanich G.P. Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory. J. Neurosci. 21 (2001) 6949-6956
16. Dean B., Mcleod M., Keriakous D., McKenzie J., and Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 7 (2002) 1083-1091
17. Do K.Q., Trabesinger A.H., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., and Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 12 (2000) 3721-3728
18. Domino E.F., Krause R.R., and Bowers J. Various enzymes involved with putative neurotransmitters. Regional distribution in the brain of deceased mentally normal, chronic schizophrenic or organic brain syndrome patients. Arch. Gen. Psychiatry 29 (1973) 195-201
19. Duncan G.E., Sheitman B.B., and Lieberman J.A. An integrated view of pathophysiological models of schizophrenia. Brains Res. Rev. 29 (1999) 250-264
20. Fadda F., Melis F., and Stancampiano R. Increased hippocampal acetylcholine release during a working memory task. Eur. J. Pharmacol. 307 (1996) R1-R2
21. Ferry B., Roozendaal B., and McGaugh J.L. Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction beta- and alpha1 adrenoreceptors. J. Neurosci. 19 (1999) 5119-5123
22. Feuerstein T.J., Gleichauf O., and Landwehrmeyer G.B. Modulation of cortical acetylcholine release by serotonin: the role of substance P interactions. Naunyn-Schmiedeberg's Arch. Pharmacol. 354 (1996) 618-626
23. Friedman J.I., Temporini H., and Davis K.L. Pharmacological strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry 45 (1999) 1-16
24. Gerber D.J., Sotnikova T.D., Gainetdinov R.R., Huang S.Y., Caron M.G., and Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. U S A 98 (2001) 15312-15317
25. Giovannini M.G., Bartolini L., Kopf S.R., and Pepeu G. Acetylcholine release from the frontal cortex during exploratory activity. Brain Res. 784 (1998) 218-227
26. Glick S.D., Maisonneuve I.M., Raucci J., and Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681 (1995) 147-152
27. Hashimoto K., Fujita Y., Shimizu E., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 519 (2005) 114-117
28. Helm K.A., Han J.-S., and Gallagher M. Effects of cholinergic lesions produced by infusions of 192 IgG-saporin on glucocorticoid receptor mRNA expression in hippocampus and medial prefrontal cortex of the rat. Neuroscience 115 (2002) 765-774
29. Hikida T., Kitabatake Y., Pastan I., and Nakanishi S. Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc. Natl. Acad. Sci. U S A 100 (2003) 6169-6173
30. Hiramatsu M., Hyodo T., and Kameyama T. U-50,488, a selective kappa opioid receptor agonist ameliorates memory impairments induced by muscarinic autoreceptor agonists, carbachol in mice. Neurosci. Lett. 236 (1997) 45-48
31. Hiramatsu M., Murasawa H., Mori H., and Kameyama T. Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous κ-opioid receptor agonist. Br. J. Pharmacol. 123 (1998) 920-926
32. Hironaka N., Tanaka K., Izaki Y., Hori K., and Nomura M. Memory-related acetylcholine efflux from rat prefrontal cortex and hippocampus: a microdialysis study. Brain Res. 901 (2001) 143-150
33. Holt D.J., Bachus S.E., Hyde T.M., Wittie M., Herman M.M., Vangel M., Saper C.B., and Kleinman J.E. Reduced density of cholinergic interneurons in the ventral striatum in schizophrenia: an in situ hybridization study. Biol. Psychiatry 58 (2005) 408-416
34. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., and Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26 (2002) 325-339
35. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
36. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
37. Jentsch J.D., Redmond Jr. D.E., Elsworth J.D., Taylor J.R., Youngren K.D., and Roth R.H. Enduring cognitive dysfunction and cortical dopamine deficits in monkeys after long-term administration of phencyclidine. Science 277 (1997) 953-955
38. Jentsch J.D., Tran A., Le D., Youngren K.D., Phil M., and Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17 (1997) 92-99
39. Jentsch J.D., Dazzi L., Chhatwal J.P., Verrico C.D., and Roth R.H. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci. Lett. 258 (1998) 175-178
40. Kaufer D., Friedman A., Seidman S., and Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 393 (1998) 373-377
41. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., and Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169 (2003) 215-233
42. Kuzmi A.V., Semenova S., Gerrits M.A., Zvartau E.E., and Van Ree J.M. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur. J. Pharmacol. 321 (1997) 265-271
43. Kilts C.D. The changing roles and targets for animal models of schizophrenia. Biol. Psychiatry 50 (2001) 845-855
44. Lacroix L., Broersen L.M., Weiner I., and Feldon J. The effects of excitotoxic lesion of the medial prefrontal cortex on latent inhibition, prepulse inhibition, food hoarding, elevated plus maze, active avoidance and locomotor activity in the rat. Neuroscience 84 (1998) 431-442
45. 3H]choline. J. Pharmacol. Exp. Ther. 225 (1983) 332-336
46. Levey A.I., Edmunds S.M., Koliatsos V., Wiley R.G., and Heilman C.J. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J. Neurosci. 15 (1995) 4077-4092
47. Mandillo S., Rinaldi A., Oliverio A., and Mele A. Repeated administration of phencyclidine, amphetamine and MK801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav. Pharmacol. 14 (2003) 533-544
48. Manikandan S., Padma M.K., Srikumar R., Parthasarathy N.J., Muthuvel A., and Devo R.S. Effects of chronic noise stress on spatial memory of rats in relation to neuronal dendritic alteration and free-radical-imbalance in hippocampus and medial prefrontal cortex. Neurosci. Lett. 399 (2006) 17-22
49. Mattsson A., Pernold K., Ogren S.O., and Olson L. Loss of cortical acetylcholine enhances amphetamine-induced locomotor activity. Neuroscience 127 (2004) 579-591
50. 1B receptors mediating inhibition of acetylcholine release. Eur. J. Pharmacol. 129 (1986) 333-337
51. McGaughy J., Koene R.A., Eichenbaum H., and Hasselmo M.E. Cholinergic deafferentation of the entorhinal cortex in rats impairs encoding of noble but not familiar stimuli in a delayed nonmatch-to-sample task. J. Neurosci. 25 (2005) 10273-10281
52. McGeer P.L., and McGeer E.G. Possible changes in striatal and limbic cholinergic systems in schizophrenia. Arch. Gen. Psychiatry 34 (1977) 1319-1323
53. McIntyre C.K., Pal S.N., Marriott L.K., and Gold P.E. Competition between memory systems: acetylcholine release in the hippocampus correlates negatively with good performance on an amygdala-dependent task. J. Neurosci. 22 (2002) 1171-1176
54. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatment of schizophrenia: a critical review of pharmacology and mechanisms of action of antipsyhotic drugs. Mol. Psychiatry 10 (2005) 79-104
55. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modeling schizophrenia. Curr. Opin. Pharmacol. 5 (2005) 101-106
56. Murai S., Saito H., Abe E., Masuda Y., Odashima J., and Itoh T. MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice. J. Neural. Transm. 98 (1994) 1-13
57. Nakamura A., Suzuki Y., Umegaki H., Ikari H., Tajima T., Endo H., and Iguchi A. Dietary restriction of choline reduces hippocampal acetylcholine release in rats: in vivo microdialysis study. Brain Res. Bull. 56 (2001) 593-597
58. Nabeshima T., Fukuya H., Yamaguchi K., Ishikawa K., Furukawa H., and Kameyama T. Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. Eur. J. Pharmacol. 135 (1987) 23-33
59. Phillips M., Wang C., and Johnson K.M. Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J. Pharmacol. Exp. Ther. 296 (2001) 905-913
60. 1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task. Brain Res. 983 (2003) 215-222
61. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Gorey J.G., Lee K.S., Egan M.F., Coppola R., and Weinberger D.R. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am. J. Psychiatry 160 (2003) 118-127
62. Ragozzino M.E., and Gold P.E. Glucose injections into the medial septum reverse the effects of intraseptal morphine output and memory. Neuroscience 68 (1995) 981-988
63. Rispoli V., Rotiroti D., Carelli V., Liberatore F., Scipione L., Marra R., Giorgioni G., and Di Stefano A. Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Mernart. Neurosci. Lett. 356 (2004) 199-202
64. Sam-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 6 (1995) 55-65
65. Sarter M., and Parikh V. Choline transporters, cholinergic transmission and cognition. Nat. Rev. Neurosci. 6 (2005) 48-56
66. Sarter M., Nelson C.L., and Bruno J. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr. Bull. 31 (2005) 117-138
67. Shannon H.E., Hart J.C., Bymaster F.P., Calligaro D.O., DeLapp N.W., Mitch C.H., Ward J.S., Fink-Jensen A., Sauerberg P., Jeppesen L., Sheardown M.J., and Swedberg M.D. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J. Pharmacol. Exp. Ther. 290 (1999) 901-907
68. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 (2002) 583-594
69. Shirayama Y., Ishida H., Iwata M., Hazama G., Kawahara R., and Duman R.S. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J. Neurochem. 90 (2004) 1258-1268
70. Smith J.E., Co C., Yin X., Sizemore G.M., Liguori A., Johnson III A.E., and Martin T.J. Involvement of cholinergic neuronal systems in intravenous cocaine self-administration. Neurosci. Biobehav. Rev. 27 (2004) 841-850
71. Spielewoy C., and Markou A. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacolgy 28 (2003) 1106-1116
72. Stanhope K.J., Mirza N.R., Bickerdike M.J., Bright J.L., Harrington N.R., Hesselink M.B., Kennett G.A., Lightowler S., Sheardown M.J., Syed R., Upton R.L., Wadsworth G., Weiss S.M., and Wyatt A. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J. Pharmacol. Exp. Ther. 299 (2001) 782-792
73. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhuo M., Liu G., and Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature 401 (1999) 63-69
74. Terry Jr. A.V., Hill W.D., Parikh V., Waller J.L., Evans D.R., and Mahadik S.P. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology 28 (2003) 300-309
75. Ueki A., and Miyosi K. Reversal of learning impairment in ventral globus pallidus-lesioned rats by combination of continuous intracerebroventricular choline infusion and oral cholinergic drug administration. Brain Res. 547 (1991) 99-109
76. Wang J.H., Fu Y., Wilson F.A., and Ma Y.Y. Ketamine affects memory consolidation: differential effects in T-maze and passive avoidance paradigms in mice. Neuroscience 140 (2006) 993-1002
77. Winkler J., Suhr S.T., Gage F.H., Thal L.J., and Fisher L.J. Essential role of neocortical acetylcholine in spatial memory. Nature 375 (1995) 484-487
78. Winters B., and Bussey T.J. Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory. J. Neurosci. 25 (2005) 4243-4251
79. A synaptic receptors. Neuroscience 113 (2002) 1-10
80. Zocchi A., and Pert A. Alterations in striatal acetylcholine overflow by cocaine, morphine, and MK-801: relationship to locomotor output. Psychopharmacology 115 (1994) 297-304